-ASC37 demonstrated statistically significant 88% greater relative body weight reduction compared to tirzepatide in the diet-induced obese (DIO) mouse model.-Both ASC37 once-monthly subcutaneous (SQ) formulation and oral formulation will be submitted to the U.S. Food and Drug Administration (FDA) v…
- Fixed-dose combination of ASC36 and ASC35 (ASC36_35 FDC) demonstrated superior weight loss compared to eloralintide in combination with tirzepatide in a diet-induced obese (DIO) animal model.HONG KONG, July 22, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces that precl…
- ASC48 is a potentially first-in-class oral small molecule GIPR agonist.- ASC48 demonstrated an EC50 of 1 pM in the hGIPR cAMP activation assay, exhibiting greater potency than tirzepatide (EC50 = 3 pM) and is a selective agonist for GIPR without activity for GLP-1R and GCGR.- ASC48 demonstrated e…
Ascletis Pharma Inc HKEX:1672:
- ASC36_35 FDC, a once-monthly subcutaneous (SQ) injection co-formulation of ASC36 and ASC35, is a potentially first-in-class drug candidate targeting three validated targets of amylin receptor, GLP-1R and GIPR.- ASC36_35 FDC demonstrated approximately 51% greater relative body weight reduction c…
